Drug Profile
DNA-hsp65
Alternative Names: DNA-hsp65 cancer immunotherapyLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Farmacore
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Head-and-neck-cancer in Brazil (Intratumoural, Injection)